Soy isoflavones for the treatment of cocaine use disorder: an open-label pilot study.
Isoflavonas de soja para el tratamiento del trastorno por consumo de cocaína: un estudio piloto abierto.
Keywords:
Cocaine, aldehyde-dehydrogenase-2 enzyme, daidzin, daidzein, soy isoflavone extract, clinical trialAbstract
Soybeans contain different isoflavones (mainly daidzein) which work as reversible inhibitors of aldehyde-dehydrogenase-2 enzyme (ALDH2). This activity has been related in animal experiments with a reduction of cocaine use. Our aim was to carry out an open-label pilot study to evaluate the possible efficacy of soy isoflavones as natural inhibitor of ALDH2 in cocaine use disorder. Nine subjects with severe cocaine use disorder participated in a single-center, open, non-controlled trial during 12 weeks of treatment and 4 of follow-up. The Substance Use Report (SUR) showed that three subjects (33.3%) reported a cocaine consumption of less than 20% (80% non-use days) from 10 to 12 weeks of the treatment period, from two (22.2%) at baseline, although non-significant. A finding that could not be confirmed by the detection of urine metabolites of cocaine. Seven participants (77.8%) completed the study at 16 weeks and one (1.11%) at 12 weeks. Urine concentrations of isoflavones, demonstrated that eight participants (88.9%) followed the treatment along the study. The Severity Dependence Scale (SDS) score showed a significant decrease between baseline to 12 weeks, baseline to 16 weeks and 12 to 16 weeks; the Brief Substance Craving Scale (BSCS) and Cocaine Selective Severity Assessment (CSSA) decreased their values but not significantly. Significant improvements in different areas of the SF-36 scale were observed: body pain scores decreased from baseline to 16 weeks statistically significant; social function improved its scores from baseline to 12 weeks and from baseline to 16 weeks significantly; the rest of areas increased their scores but not significantly. These findings show lower ratios of cocaine use days, and high retention and adherence to treatment although the acquisition of complete abstinence was not observed. Soy isoflavones could be considered a potential treatment in future research, to be confirmed by placebo-controlled studies with adequate sample size.References
Al-Halabí, S., Sáiz, P. A., Burón, P., Garrido, M., Benabarre, A., Jiménez, E., Cervilla, J., Navarrete, M. I., Díaz-Mesa, E. M., García-Álvarez, L., Muñiz, J., Posner, K., Oquendo, M. A., García-Portilla, M. P. y Bobes, J. (2016). Validación de la versión en español de la Columbia-Suicide Severity Rating Scale (Escala Columbia para evaluar el riesgo de suicidio). Revista de Psiquiatría y Salud Mental, 9(3), 134–142. https://doi.org/10.1016/j.rpsm.2016.02.002
Alonso, J., Prieto, L. y Antó, J. M. (1995). La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): Un instrumento para la medida de los resultados clínicos. Medicina Clínica, 104(20), 771–776.
Alvarez, Y., Farré, M., Fonseca, F. y Torrens, M. (2010). Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis. Journal of Substance Abuse Treatment, 38(1), 66–73. https://doi.org/10.1016/j.jsat.2009.07.001
Álvarez, Y., Pérez-Mañá, C., Torrens, M. y Farré, M. (2013). Antipsychotic drugs in cocaine dependence: A systematic review and meta-analysis. Journal of Substance Abuse Treatment, 45(1), 1–10. https://doi.org/10.1016/j.jsat.2012.12.013
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). American Psychiatric Publishing.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
Amygdala Neurosciences. (n.d.). Amygdala Neurosciences. https://amygns.com/
Araos, P., Vergara-Moragues, E., González-Saiz, F., Pedraz, M., García-Marchena, N., Romero-Sanchiz, P., Ruiz, J. J., Campos-Cloute, R., Serrano, A., Pavón, F. J., Torrens, M. y Rodriguez de Fonseca, F. (2017). Differences in the rates of drug polyconsumption and psychiatric comorbidity among patients with cocaine use disorders according to the mental health service. Journal of Psychoactive Drugs, 49(4), 306–315. https://doi.org/10.1080/02791072.2017.1342151
Arolfo, M. P., Overstreet, D. H., Yao, L., Fan, P., Lawrence, A. J., Tao, G., Keung, W. M., Vallee, B. L., Olive, M. F., Gass, J. T., Rubin, E., Anni, H., Hodge, C. W., Besheer, J., Zablocki, J., Leung, K., Blackburn, B. K., Lange, L. G. y Diamond, I. (2009). Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcoholism: Clinical and Experimental Research, 33(11), 1935–1944. https://doi.org/10.1111/j.1530-0277.2009.01031.x
Ashok, A. H., Mizuno, Y., Volkow, N. D. y Howes, O. D. (2017). Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine. JAMA Psychiatry, 74(5), 511–519. https://doi.org/10.1001/jamapsychiatry.2017.0135
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M. y Halpern, C. H. (2021). Comparison of treatments for cocaine use disorder among adults. JAMA Network Open, 4(5), e218049. https://doi.org/10.1001/jamanetworkopen.2021.8049
Bobes, J., Bulbena, A., Luque, A., Dal-Ré, R., Ballesteros, J., Ibarra, N. y Grupo de Validación en Español de Escalas Psicométricas. (2003). A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale. Medicina Clínica, 120(18), 693–700.
Borroto-Escuela, D. O., Narváez, M., Romero-Fernández, W., Pinton, L., Wydra, K., Filip, M., Beggiato, S., Tanganelli, S., Ferraro, L. y Fuxe, K. (2019). Acute cocaine enhances dopamine D2R recognition and signaling and counteracts D2R internalization in Sigma1R-D2R heteroreceptor complexes. Molecular Neurobiology, 56(10), 7045–7055. https://doi.org/10.1007/s12035-019-1580-8
Borroto-Escuela, D. O., Narváez, M., Wydra, K., Pintsuk, J., Pinton, L., Jimenez-Beristain, A., Di Palma, M., Jastrzębska, J., Filip, M. y Fuxe, K. (2017). Cocaine self-administration specifically increases A2AR-D2R and D2R-Sigma1R heteroreceptor complexes in the rat nucleus accumbens shell: Relevance for cocaine use disorder. Pharmacology, Biochemistry and Behavior, 155, 24–31. https://doi.org/10.1016/j.pbb.2017.03.003.
Borroto-Escuela, D. O., Wydra, K., Filip, M. y Fuxe, K. (2018). A2AR-D2R heteroreceptor complexes in cocaine reward and addiction. Trends in Pharmacological Sciences, 39(12), 1008–1020. https://doi.org/10.1016/j.tips.2018.10.007
Cacciola, J. S., Alterman, A. I., McLellan, A. T., Lin, Y.-T. y Lynch, K. G. (2007). Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug and Alcohol Dependence, 87(2–3), 297–302. https://doi.org/10.1016/j.drugalcdep.2006.09.002
Camí, J. y Farré, M. (2003). Drug addiction. The New England Journal of Medicine, 349(10), 975–986. https://doi.org/10.1056/NEJMra023160
Carmignani, L. O., Pedro, A. O., Costa-Paiva, L. H. y Pinto-Neto, A. M. (2010). The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: A randomized controlled trial. Maturitas, 67(3), 262–269. https://doi.org/10.1016/j.maturitas.2010.07.007
Carroll, K. M., Nich, C., Petry, N. M., Eagan, D. A., Shi, J. M. y Ball, S. A. (2016). A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug and Alcohol Dependence, 160, 135–142. https://doi.org/10.1016/j.drugalcdep.2015.12.036
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X. y Capellà, D. (2016). Psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews, 2016(9), CD007380. https://doi.org/10.1002/14651858.CD007380.pub4
Ciccarone, D. y Shoptaw, S. (2022). Understanding stimulant use and use disorders in a new era. Medical Clinics of North America, 106(1), 81–97. https://doi.org/10.1016/j.mcna.2021.08.010
Compton, W. M. y Volkow, N. D. (2024). Reductions in substance use as outcome targets for treatment development. American Journal of Psychiatry, 181(11), 947–948. https://doi.org/10.1176/appi.ajp.20240841
Darke, S., Hall, W., Heather, N., Ward, J. y Wodak, A. (1991). The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS, 5(2), 181–185.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2024). European Drug Report 2024: Trends and developments. https://www.emcdda.europa.eu/publications/european-drug-report/2024_en
Farré, M., de la Torre, R., González, M. L., Terán, M. T., Roset, P. N., Menoyo, E. y Camí, J. (1997). Cocaine and alcohol interactions in humans: Neuroendocrine effects and cocaethylene metabolism. The Journal of Pharmacology and Experimental Therapeutics, 283(1), 164–176.
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., Shoptaw, S. y McKetin, R. (2019). Responding to global stimulant use: Challenges and opportunities. The Lancet, 394(10209), 1652–1667. https://doi.org/10.1016/S0140-6736(19)32230-5
Fernàndez-Castillo, N., Cabana-Domínguez, J., Corominas, R. y Cormand, B. (2021). Molecular genetics of cocaine use disorders in humans. Molecular Psychiatry, 27(1), 624–639. https://doi.org/10.1038/s41380-021-01256-1
Gaval-Cruz, M. y Weinshenker, D. (2009). Mechanisms of disulfiram-induced cocaine abstinence: Antabuse and cocaine relapse. Molecular Interventions, 9(4), 175–187. https://doi.org/10.1124/mi.9.4.6
González-Saiz, F., de las Cuevas, C., Barrio, G. y Domingo-Salvany, A. (2008). Spanish version of the Severity of Dependence Scale (SDS). Medicina Clínica, 131(20), 797–798.
Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Rockville, MD.
Hirsiger, S., Hänggi, J., Germann, J., Vonmoos, M., Preller, K. H., Engeli, E. J. E., Kirschner, M., Reinhard, C., Hulka, L. M., Baumgartner, M. R., Chakravarty, M. M., Seifritz, E., Herdener, M. y Quednow, B. B. (2019). Longitudinal changes in cocaine intake and cognition are linked to cortical thickness adaptations in cocaine users. NeuroImage: Clinical, 21, 101652. https://doi.org/10.1016/j.nicl.2019.101652
Indave, B. I., Minozzi, S., Pani, P. P. y Amato, L. (2016). Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews, 2016(6), CD006306. https://doi.org/10.1002/14651858.CD006306.pub3
Kampangkaew, J. P., Spellicy, C. J., Nielsen, E. M., Harding, M. J., Ye, A., Hamon, S. C., Kosten, T. R. y Nielsen, D. A. (2019). Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. The American Journal of Addictions, 28(4), 311–317. https://doi.org/10.1111/ajad.12891
Kampman, K. M., Volpicelli, J. R., McGinnis, D. E., Alterman, A. I., Weinrieb, R. M., D’Angelo, L. y Epperson, L. E. (1998). Reliability and validity of the Cocaine Selective Severity Assessment. Addictive Behaviors, 23(4), 449–461.
Kampman, K. M. (2019). The treatment of cocaine use disorder. Science Advances, 5(10), eaax1532. https://doi.org/10.1126/sciadv.aax1532
Khaodhiar, L., Ricciotti, H. A., Li, L., Pan, W., Schickel, M., Zhou, J. y Blackburn, G. L. (2008). Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause, 15(1), 125–132.
Kohut, S. J. y Bergman, J. (2017). Medication strategies for the management of cocaine use disorder.. The Neuroscience of Cocaine (pp. 627–637). Elsevier. https://doi.org/10.1016/B978-0-12-803750-8.00063-4
Koob, G. F. y Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238. https://doi.org/10.1038/npp.2009.110
Koppaka, V., Thompson, D. C., Chen, Y., Ellermann, M., Nicolaou, K. C., Juvonen, R. O., Petersen, D., Deitrich, R. A., Hurley, T. D. y Vasiliou, V. (2012). Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacological Reviews, 64(3), 520–539. https://doi.org/10.1124/pr.111.005538
Li, X. y Wolf, M. E. (2015). Multiple faces of BDNF in cocaine addiction. Behavioural Brain Research, 279, 240–254. https://doi.org/10.1016/j.bbr.2014.11.018
Lowe, E. D., Gao, G. Y., Johnson, L. N. y Keung, W. M. (2008). Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. Journal of Medicinal Chemistry, 51(15), 4482–4487. https://doi.org/10.1021/jm800488j
Lu, L., Liu, Y., Zhu, W., Shi, J., Liu, Y, Ling, W. y Kosten, T. R. (2009). Traditional medicine in the treatment of drug addiction. The American Journal of Drug and Alcohol Abuse, 35(1), 1–11. https://doi.org/10.1080/00952990802455469
Lu, Y., Zhu, S., He, Y., Peng, C., Wang, Z. y Tang, Q. (2019). Phytochemical profile and antidepressant effect of Ormosia henryi Prain leaf ethanol extract. International Journal of Molecular Sciences, 20(14), 3396. https://doi.org/10.3390/ijms20143396
Lukas, S. E., Penetar, D., Su, Z, Geaghan, T., Maywalt, M., Tracy, M., Rodolico, J., Palmer, C., Ma, Z. y Lee, D. Y. W. (2013). A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkers. Psychopharmacology, 226(1), 65–73. https://doi.org/10.1007/s00213-012-2884-9
Machin, D., Campbell, M. J., Tan, S. B. y Tan, S. H. (2009). Sample size tables for clinical studies: Chapter 16, Phase II trials. Wiley-Blackwell. pp. 207–236.
Martin, M., Gutiérrez-Martos, M., Cabrera, R., Langohr, K., Maldonado, R., Farré, M. y de la Torre, R. (2021). Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice. Psychopharmacology, 238(7), 1923–1936. https://doi.org/10.1007/s00213-021-05820-z
Martínez-Riera, R., Pérez-Mañá, C., Papaseit, E., Fonseca, F., de la Torre, R., Pizarro, N. y Torrens, M., Farré, M. (2019). Soy isoflavone extract does not increase the intoxicating effects of acute alcohol ingestion in human volunteers. Frontiers in Pharmacology, 10, 131. https://doi.org/10.3389/fphar.2019.00131
McGinty, J. F. (2022). BDNF as a therapeutic candidate for cocaine use disorders. Addiction Neuroscience, 2, 100006. https://doi.org/10.1016/j.addicn.2022.100006
Milton, A. L. y Everitt, B. J. (2012). The persistence of maladaptive memory: Addiction, drug memories and anti-relapse treatments. Neuroscience & Biobehavioral Reviews, 36(4), 1119–1139. https://doi.org/10.1016/j.neubiorev.2012.01.002
Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M. F., Pani, P. P. y Vecchi, S. (2015). Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews, 2015(10), CD006754. https://doi.org/10.1002/14651858.CD006754.pub4
Overstreet, D. H., Keung, W. M., Rezvani, A. H., Massi, M. y Lee, D. Y. W. (2003). Herbal remedies for alcoholism: Promises and possible pitfalls. Alcoholism: Clinical and Experimental Research, 27(2), 177–185. https://doi.org/10.1097/01.ALC.0000051022.26489.CF
Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S. y Davoli, M. (2010). Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews, 2010(1), CD007024. https://doi.org/10.1002/14651858.CD007024.pub2
Pani, P. P., Trogu, E., Vecchi, S. y Amato, L. (2011). Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews, 2011(12), CD002950. https://doi.org/10.1002/14651858.CD002950.pub3
Paquette, C. E., Daughters, S. B. y Witkiewitz, K. (2022). Expanding the continuum of substance use disorder treatment: Nonabstinence approaches. Clinical Psychology Review, 91, 102110. https://doi.org/10.1016/j.cpr.2021.102110
Penetar, D. M., MacLean, R. R., McNeil, J. F. y Lukas, S. E. (2011). Kudzu extract treatment does not increase the intoxicating effects of acute alcohol in human volunteers. Alcoholism: Clinical and Experimental Research, 35(4), 726–734. https://doi.org/10.1111/j.1530-0277.2010.01390.x
Penetar, D. M., Toto, L. H., Lee, D. Y. W. y Lukas, S. E. (2015). A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm. Drug and Alcohol Dependence, 153, 194–200. https://doi.org/10.1016/j.drugalcdep.2015.05.025
Pérez de los Cobos, J., Trujols, J., Siñol, N., Vasconcelos e Rego, L., Iraurgi, I. y Batlle, F. (2014). Psychometric properties of the Spanish version of the Cocaine Selective Severity Assessment to evaluate cocaine withdrawal in treatment-seeking individuals. Journal of Substance Abuse Treatment, 47(3), 189–196. https://doi.org/10.1016/j.jsat.2014.05.004
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M. y Capellà, D. (2011). Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. Journal of Substance Abuse Treatment, 40(2), 109–122. https://doi.org/10.1016/j.jsat.2010.08.012
Reback, C. J., Larkins, S. y Shoptaw, S. (2004). Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS and Behavior, 8(1), 87–98. https://doi.org/10.1023/B:AIBE.0000017528.39338.75
Rodríguez-Morató, J., Farré, M., Pérez-Mañá, C., Papaseit, E., Martínez-Riera, R., de la Torre, R. y Pizarro, N. (2015). Pharmacokinetic comparison of soy isoflavone extracts in human plasma. Journal of Agricultural and Food Chemistry, 63(31), 6946–6953. https://doi.org/10.1021/acs.jafc.5b02891
RxList. (n.d.). Soy: Uses and effectiveness. RxList. https://www.rxlist.com/soy/supplements.htm#UsesAndEffectiveness
Schroeder, J. P., Cooper, D. A., Schank, J. R., Lyle, M. A., Gaval-Cruz, M., Ogbonmwan, Y. E., Pozdeyev, N., Freeman, K. G., Iuvone, P. M., Edwards, G. L., Holmes, P. V. y Weinshenker, D. (2010). Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase. Neuropsychopharmacology, 35(12), 2440–2449. https://doi.org/10.1038/npp.2010.127
Smith, L. J., Kalhan, R., Wise, R. A., Sugar, E. A., Lima, J. J., Irvin, C. G., Dozor, A. J. y Holbrook, J. T. (2015). Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma. JAMA, 313(20), 2033–2043. https://doi.org/10.1001/jama.2015.5024
Somoza, E., Dyrenforth, S., Goldsmith, J., Mezinskis, J. y Cohen, M. (1995). In search of a universal drug craving.. Annual Meeting of the American Psychiatric Association.
Stotts, A. L., Mooney, M. E., Sayre, S. L., Novy, M., Schmitz, J. M. y Grabowski, J. (2007). Illusory predictors: Generalizability of findings in cocaine treatment retention research. Addictive Behaviors, 32(12), 2819–2836. https://doi.org/10.1016/j.addbeh.2007.04.020
Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A. y Sellers, E. M. (1989). Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). The British Journal of Addiction, 84(11), 1353–1357.
Tantipongpiradet, A., Monthakantirat, O., Vipatpakpaiboon, O., Khampukdee, C., Umehara, K., Noguchi, H., Fujiwara, H., Matsumoto, K., Sekeroglu, N., Kijjoa, A. y Chulikhit, Y. (2019). Effects of puerarin on the ovariectomy-induced depressive-like behavior in ICR mice and its possible mechanism of action. Molecules, 24(24), 4569. https://doi.org/10.3390/molecules24244569
Torrens, M., Martínez-Sanvisens, D., Martínez-Riera, R., Bulbena, A., Szerman, N. y Ruiz, P. (2011). Dual diagnosis. Addictive Disorders & Their Treatment, 10(2), 50–59. https://doi.org/10.1097/ADT.0b013e318215f322
Torrens, M., Serrano, D., Astals, M., Pérez-Domínguez, G. y Martín-Santos, R. (2004). Diagnosing comorbid psychiatric disorders in substance abusers: Validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. The American Journal of Psychiatry, 161(7), 1231–1237. https://doi.org/10.1176/appi.ajp.161.7.1231
United Nations Office on Drugs and Crime (UNODC). (2024). World Drug Report 2024. United Nations.
Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D. y Telang, F. (2011). Addiction: Beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences, 108(37), 15037–15042. https://doi.org/10.1073/pnas.1010654108
Volkow, N. D. (2020). Personalizing the treatment of substance use disorders. American Journal of Psychiatry, 177(2), 113–116. https://doi.org/10.1176/appi.ajp.2019.19121284
Weinshenker, D. (2010). Cocaine sobers up. Nature Medicine, 16(9), 969–970. https://doi.org/10.1038/nm0910-969
Weiss, R. D., Hufford, C., Najavits, L. M. y Shaw, S. R. (1995). Weekly Substance Use Inventory. Unpublished measure, Harvard Medical School, Boston.
Yang, T. S., Wang, S. Y., Yang, Y. C., Su, C. H., Lee, F. K., Chen, S. C., Tseng, C. Y., Jou, H. J., Huang, J. P. y Huang, K. E. (2012). Effects of standardized phytoestrogen on Taiwanese menopausal women. Taiwanese Journal of Obstetrics and Gynecology, 51(2), 229–235. https://doi.org/10.1016/j.tjog.2012.04.011
Yao, L., Fan, P., Arolfo, M., Jiang, Z., Olive, M. F., Zablocki, J., Sun, H., Chu, N., Lee, J., Kim, H., Leung, K., Shryock, J., Blackburn, B. y Diamond, I. (2010). Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use–dependent inhibitor of dopamine synthesis. Nature Medicine, 16(9), 1024–1028. https://doi.org/10.1038/nm.2200
